Desogestrel and gestodene in oral contraceptives: 12 months’ assessment of carbohydrate and lipoprotein metabolism

Obstetrics and Gynecology

Volumn 78, Issue 4, 1991, Pages 666-672

  Petersen, Kresten Rubeck ^a   Skouby, Sven Olaf ^a   Pedersen, Rikke Grønholt ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE; DESOGESTREL; ETHINYLESTRADIOL; GESTODENE; LIPOPROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; METABOLISM; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; CARBOHYDRATES; CONTRACEPTIVES, ORAL; DESOGESTREL; DRUG THERAPY, COMBINATION; ETHINYL ESTRADIOL; FEMALE; HUMAN; LIPOPROTEINS; METABOLISM; NORPREGNENES; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 0025858433     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Clifford KR. Progestogens and arterial disease—evidence from the Royal College of General Practitioners’ study. Am J Obstet Gynecol 1982;142:762–5.
2. Fotherby K. Oral contraceptives, lipids and cardiovascular disease. Contraception 1985;31:367–94.
3. Crook D, Godsland IF, Wynn V. Oral contraceptives and coronary heart disease: Modulation of glucose tolerance and plasma lipid risk factors by progestins. Am J Obstet Gynecol 1988;158:1612–20.
4. Skouby SO. The influence on the pituitary-ovarian function, cervical mucus and vaginal cytology of a new progestational compound. Contraception 1977;14:529–39.
5. Spona J, Schneider WHF, Bieglmayer C, Schroeder R, Pirker R. Ovulation inhibition with different doses of levonorgestrel and other progestogens: Clinical and experimental investigations. Acta Obstet Gynecol Scand Suppl 1979;88:7–15.
6. Eyoung E, Buchi K, Elstein M. Effects of 180 mcg and 250 mcg norgestimate on the pituitary-ovarian function and cervical mucus. Fertil Steril 1988;50:756–60.
7. Bergink EW, Kloosterboer HJ. Structural requirements for optimal receptor binding of contraceptive progestogens. Adv Contracept 1985;1:256.
8. Dolhofer R, Weiss L, Wieland OH. Experience with the glucose-dehydrogenase-UV-method for the determination of blood glucose. J Clin Chem Clin Biochem 1976;14:415–7.
9. Kühl C. Glucose metabolism during and after pregnancy in normal and gestational diabetic women. Acta Endocrinol 1975;79:709–19.
10. Talameh Y, Wei R, Naito H. Measurement of total HDL, HDL2 and HDL3 by dextran sulfate-MgCl2 precipitation technique in human serum. Clin Chim Acta 1986;158:33–41.
11. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499–502.
12. Böttiger LE, Boman G, Eklund G, Westerholm B. Oral contraceptives and thromboembolic disease: Effect of lowering estrogen content. Lancet 1980;i:1097–101.
13. Meade TW, Greenberg G, Thompsom SG. Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30μg oestrogen preparations. Br Med J 1980;280:1157–61.
14. Spellacy WN. Carbohydrate metabolism during treatment with estrogens, progestogen, and low dose oral contraceptives. Am J Obstet Gynecol 1982;142:732–4.
15. Wynn V, Godsland I. Effect of oral contraceptives on carbohydrate metabolism. J Reprod Med 1986;9:893–7.
16. Perlman JA, Russell-Briefel R, Ezzati T, Lieberknecht G. Oral glucose tolerance and the potency of contraceptive progestins. J Chronic Dis 1985;38:857–64.
17. Pyorala K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: Results from two population studies in Finland. Diabetes Care 1979;2:131–41.
18. Stout RW. Insulin and atheroma—an update. Lancet 1987;i:1077–9.
19. Gaspard UJ, Lefebvre PJ. Clinical aspects of the relationship between oral contraceptives, abnormalities in carbohydrate metabolism, and the development of cardiovascular disease. Am J Obstet Gynecol 1990;163:334–43.
20. van der Ende, Lütjens A, van Wayjen RGA, Kloosterboer HJ. Effects of the oral contraceptive combination 0.150 mg desogestrel plus 0.020 mg ethinyl estradiol on carbohydrate metabolism in healthy female volunteers. Acta Obstet Gynecol Scand Suppl 1987;144:29–32.
21. Fioretti P, Fruzzetti F, Navalesi R, et al. Clinical and metabolic study of a new pill containing 20 mcg ethinyl estradiol plus 0. 150 mg desogestrel. Contraception 1987;35:229–43.
22. Fotherby K, Trayner I, Longthorne PN, Lee B, Watson HR. Metabolic investigations with Femodene—an oral contraceptive containing gestodene and ethinyloestradiol. Contraception 1987; 35:323–37.
23. Crosignani PG, Vergadora F, Giudici GA, et al. A study of the metabolic effects of monophasic gestodene and desogestrel preparations. In: Elstein M, eds. Gestodene. Development of a new gestodene-containing low-dose oral contraceptive. Carnforth, England: Parthenon, 1988:105–11.
24. Wynn V. Effect of duration of low-dose oral contraceptive administration on carbohydrate metabolism. Am J Obstet Gynecol 1982;142:739–46.
25. Petersen KR, Skouby SO, Drelsler A, Kuhl C, Svenstrup B. Comparative trial of the effects on glucose tolerance and lipoprotein metabolism of two new oral contraceptives containing gestodene and desogestrel. Acta Obstet Gynecol Scand 1988;67:37–41.
26. Harvengt C, Desager JP, Gaspard U, Lepot M. Changes in lipoprotein composition in women receiving two low-dose oral contraceptives containing ethinyl estradiol and gonane progestins. Contraception 1988;37:565–75.
27. Bradley DD, Wingerd J, Petitti DB, Krauss RM, Ramcharan S. Serum high-density-lipoprotein cholesterol in women using oral contraceptives, estrogens and progestins. N Engl J Med 1978;299:17–20.
28. Tikkanen MJ, Nikkilä EA, Kuusi T, Sipinen S. Effects of oestradiol and levonorgestrel on lipoprotein lipids and postheparin lipase activities in normolipoproteinaemic women. Acta Endocrinol 1982;99:630–5.
29. Gordon T, Castalli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham study. JAMA 1977;62:707–14.
30. Miller NE, Førde OH, Thelel DS, Mjøs OD. The Tromsø Heart study. High density lipoprotein and coronary heart disease: A prospective case-control study. Lancet 1977;i:965–7.
31. Lewis B. The lipoproteins: Predictors, protectors and pathogens. Br Med J 1983;287:1161–4.
32. Tuimala R, Korhonen M, Kortesluma M. Effects of the oral contraceptive combination 0.150 mg desogestrel + 0.020 mg ethinyl estradiol on serum lipids, SHBG, glycosylated proteins and plasma antithrombin III in healthy women. Acta Obstet Gynecol Scand Suppl 1987;144:37–9.
33. Kloosterboer HJ, van Wayjen RGA, van den Ende A. Effects of the oral contraceptive combination 0.150 mg desogestrel + 0.020 mg ethinyl estradiol on serum lipids, including the HDL subfractions. Acta Obstet Gynecol Scand Suppl 1987;144:33–6.
34. März W, Jung-Hoffmann F, Heidt F, Gross W, Kuhl H. Changes in lipid metabolism during 12 months of treatment with two oral contraceptives containing 30 μg ethinylestradiol and 75 μg gestodene or 150 μg desogestrel. Contraception 1990;41:245–58.
35. Tikkanen MJ. Role of plasma lipoproteins in the pathogenesis of atherosclerotic disease, with special reference to sex hormone effects. Am J Obstet Gynecol 1990;163:296–304.
36. Taskinen MR, Nikkilä EA. High density lipoprotein subfractions in relation to lipoprotein lipase activity of tissues in man— evidence for reciprocal regulation of HDL2 and HDL3 levels by lipoprotein lipase. Clin Chim Acta 1981;112:325–32.
37. Simpson HC, Mann JI, Meade TW. Hypertriglyceridemia and hypercoagulability. Lancet 1983;i:786–90.
38. Stuart MJ, Gerrard JM, White JG. Effect of cholesterol on production of thromboxane B2 by platelets in vitro. N Engl J Med 1980;302:6–10.